ONCOLOGY COE
Medical oncology should be considered when a family needs review of treatments that act throughout the body, such as chemotherapy, targeted therapy, immunotherapy or cell therapy. A doctor must review pathology, biomarkers, imaging, prior treatment, patient fitness and care goals before deciding which options are relevant.
It is not simply about choosing a drug. The team reviews pathology, biomarkers, previous treatment, fitness and family goals to frame the right clinical questions.
This pathway is for families seeking clarity on systemic options—chemotherapy, targeted therapy, immunotherapy or cell therapy—after a new diagnosis, an inadequate response, recurrence or an unclear plan.
COMMON QUESTIONS
Review may be needed after a new diagnosis, when cancer is advanced or recurrent, after an inadequate treatment response, or when the sequence of chemotherapy, targeted therapy, immunotherapy and cell therapy is unclear. A doctor makes the formal decision after reviewing the complete case.
Prepare pathology reports, recent imaging and radiology reports, a dated treatment history with responses, available biomarker or molecular-test results, and information about daily function, nutrition and comorbidities.
No. Suitability depends on the diagnosis, biomarkers, prior treatment, patient fitness, clinical evidence, regulatory approval and hospital review. A technology name alone is not enough to determine treatment.
START HERE
A new diagnosis requiring a complete treatment strategy
Advanced or recurrent cancer after multiple treatment lines
Questions about biomarkers, immunotherapy, targeted therapy or CAR-T
A second opinion on sequencing treatment and monitoring
RELEVANT ADVANTAGES
Pathology, biomarkers, imaging, treatment history and patient fitness are reviewed as one story, not separate reports.
Discussion may cover chemotherapy, immunotherapy, targeted therapy and cell therapy; the doctor decides what is relevant.
For relapsed or refractory lymphoma or selected gastric cancers, a coordinator can ask the hospital to assess diagnosis, prior lines, biomarkers and formal eligibility.
When medication alone does not answer the question, the case can be routed to discuss radiotherapy, intervention or oncologic surgery.
DOCTORS & TEAMS
The reviewing doctor, schedule and hospital are formally confirmed after initial records are reviewed.
Precision oncology and immunotherapy
Guangzhou Fosun Chancheng Hospital
Medical oncology, hematology and cell therapy
Foshan Fosun Chancheng Hospital
PROGRAMS & TECHNOLOGY
A CASE LENS
A family with advanced gastric cancer brings pathology, HER2, PD-L1 and other biomarker results, recent imaging, and the sequence of chemotherapy and immunotherapy. The question is not “will CAR-T definitely work?” but “should CLDN18.2 be tested, is there an authorised cell-therapy pathway, and what are the alternatives if it is not suitable?”
Educational scenario based on 2026 CAR-T materials; not a promised patient outcome.
PREPARATION
MEMBER HOSPITALS
Foshan Fosun Chancheng Hospital · Foshan, Guangdong
A Fosun Health member hospital in the Greater Bay Area for complex-condition and family pathways.
One place to explore oncology, cardiovascular, orthopedics/spine, urology, and women’s and children’s health—with the plan confirmed by the hospital.
A strong option when a family needs to map several specialist needs in one clear conversation, then request official confirmation of doctors, technology, and next steps.
Guangzhou Fosun Chancheng Hospital · Guangzhou, Guangdong
A Fosun Health member hospital in Guangzhou for oncology, minimally invasive surgery, and neurosciences pathways.
Start with the precise question: does the case call for medical oncology, interventional therapy, surgical oncology, or neurology and stroke assessment? The hospital determines pathway fit.
Well suited to families who want to turn reports or imaging into sharper clinical questions before choosing a journey and hospital.
SOURCES & BOUNDARIES
| Material | Date | Used for |
|---|---|---|
| Dr. Tao Chen Oncology Profile v2 | 11 May 2026 | Doctor profile and precision-oncology focus |
| Fosun Health Oncology Campaign Clinical Portfolio | 22 June 2026 | Local, systemic and surgical treatment matrix |
| Gastric CAR-T Physician Training Material | 1 July 2026 | CLDN18.2 question criteria; use follows official approval |
Source materials are official Fosun Health or member-hospital documents supplied to BKC. This page does not publish internal targets, identifiable patient data, fixed prices, SLAs or outcome claims. Doctors and hospitals confirm current applicability for each case.
AI provides general service information only, not diagnosis or treatment recommendations.